Alternative Complement Pathway Inhibition by Lampalizumab
Purpose: Lampalizumab, an antigen-binding fragment of a humanized monoclonal antibody directed against complement factor D (CFD), is designed to treat geographic atrophy (GA) secondary to age-related macular degeneration. Given the lack of clinical efficacy observed in patients with GA in the phase...
Main Authors: | Rose Edmonds, MS, Verena Steffen, MSc, Lee A. Honigberg, PhD, Michael C. Chang, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Ophthalmology Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666914523000180 |
Similar Items
-
The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy
by: Rose Edmonds, MS, et al.
Published: (2023-12-01) -
Editorial: The complement system in autoimmunity
by: Eveline Y. Wu, et al.
Published: (2022-11-01) -
Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration
by: Prem N. Patel, et al.
Published: (2022-08-01) -
Chroman and related compounds/
by: 428668 Drewes, Siegfried E.
Published: (1974) -
DYSFUNCTION OF COMPLEMENT SYSTEM IN FAMILIAL MEDITERRANEAN FEVER
by: G. M. Mkrtchyan, et al.
Published: (2014-07-01)